3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
7
Not yet recruiting
2
Terminated
1
Suspended
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Classical hematology
1
Conditions
Carcinoma, Non-Small-Cell Lung
46
Neoplasms
34
Breast Neoplasms
34
Melanoma
26
Neoplasm Metastasis
24
Leukemia, Myeloid, Acute
21
Colorectal Neoplasms
20
Prostatic Neoplasms
19
Lung Neoplasms
17
Multiple Myeloma
16
Ovarian Neoplasms
14
Recurrence
13
Myelodysplastic Syndromes
13
Lymphoma, Non-Hodgkin
13
Squamous Cell Carcinoma of Head and Neck
12
Carcinoma, Renal Cell
12
Uterine Cervical Neoplasms
11
Lymphoma, Large B-Cell, Diffuse
11
Carcinoma, Hepatocellular
11
Urinary Bladder Neoplasms
10
Pancreatic Neoplasms
10
Glioblastoma
10
Brain Neoplasms
10
Stomach Neoplasms
8
Head and Neck Neoplasms
8
Triple Negative Breast Neoplasms
7
Rectal Neoplasms
7
Lymphoma, Follicular
7
Lymphoma
7
Hodgkin Disease
7
Interventions
abelacimab
1
MAA868
1
Dalteparin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Venous Thromboembolism
×
90 days
×
Clear all
NCT05171075
2026-04-17
MAGNOLIA
Anthos Therapeutics, Inc.
Phase 3
Terminated
417 enrolled